MONTREAL, Sept. 4 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug
development company focused on developing therapies for the inhalation and
pain markets, today announced that Finnish Regulatory Authorities have been
the first one to grant approval to initiate a Phase 3 clinical study with
Fentanyl TAIFUN(R). Further approvals are expected in the near future.
